March 20, 2018 4:19 PM ET


Company Overview of OOO "Gepatera"

Company Overview

OOO "Gepatera", a biotechnology company, develops drugs for the prevention and treatment liver disease. It is developing medicine to treat chronic virus Hepatitis B and D. The company was founded in 2011 and is based in the Russian Federation.



Founded in 2011

Key Executives for OOO "Gepatera"

OOO "Gepatera" does not have any Key Executives recorded.

OOO "Gepatera" Key Developments

Hepatera LLC Announces Positive Interim Results of Phase 2B Clinical Program of Myrcludex B

Hepatera LLC and it's development partner MYR GmbH announced positive interim results in MYR 202 clinical trial, a Phase 2b study investigating Myrcudex B in chronic hepatitis delta infection. 120 subjects have been enrolled into this study in 15 centers in Russia and Germany and have completed active treatment phase. After 24 weeks of treatment, Myrcludex demonstrated excellent safety profile with no drug-related SAEs or treatment discontinuations due to the study drug. Patient`s adherence to the treatment was very high. The primary endpoint, HDV RNA decline >2log10 or negativation was met for all doses of Myrcludex B. In the 10mg treatment group, the endpoint was achieved by 76.6% of patients, vs 3.3% in control arm. Median HDV RNA decline was 2.7log10 in 10mg arm, vs. 0.18log10 in control arm. Myrcludex treatment was associated with marked biochemical response in all Myrcludex arms, but not in the control arm. At week 24, 40% of patients in 10mg arm achieved ALT normalization (6.6% in control arm). Median ALT levels in 10mg and control arm were 43 U/L and 76 U/L, respectively. All differences between Myrcludex and control arm were highly statistically significant. Importantly, trends to decrease in liver stiffness and a decrease of intrahepatic HDV RNA levels were observed in Myrcludex arms. The interim results of the trial were presented at the recent American Association for the Study of Liver Diseases Conference by Prof. Heiner Wedemeyer (Hannover Medical School, Germany).

Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta

Hepatera LLC and its development partner MYR GmbH announced the completion of recruitment for MYR 202 and 203 clinical trials, a Phase 2b program investigating Myrcudex B in chronic hepatitis delta infection.

Hepatera LLC and MYR GmbH Announce Results of the First-In-Man Phase 1 Study in Healthy Volunteers

Hepatera LLC and it's development partner MYR GmbH announced that the results of the first-in-man Phase 1 study in healthy volunteers, and the proof-of-concept Phase 2a study in HBV/HDV co-infected patients were published as two separate back-to-back articles in Journal of Hepatology and are available online.

Similar Private Companies By Industry

Company Name Region
Albiotech Europe
Alkor Bio Ltd. Europe
Antioksidant, OOO Europe
Aquanova Rus CJSC Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OOO Gepatera, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at